Advertisement
Canada markets open in 1 hour 15 minutes
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7323
    -0.0001 (-0.01%)
     
  • CRUDE OIL

    84.39
    +0.82 (+0.98%)
     
  • Bitcoin CAD

    87,910.77
    +455.22 (+0.52%)
     
  • CMC Crypto 200

    1,385.96
    -10.58 (-0.76%)
     
  • GOLD FUTURES

    2,357.20
    +14.70 (+0.63%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • NASDAQ futures

    17,738.25
    +170.75 (+0.97%)
     
  • VOLATILITY

    15.62
    +0.25 (+1.63%)
     
  • FTSE

    8,114.77
    +35.91 (+0.44%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6832
    +0.0011 (+0.16%)
     

Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?

Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?

The company also continues to benefit from sales of blockbusters including blood thinner Eliquis and oncology drug Ibrance. In fact, Pfizer expects patent losses alone to lead to $17 billion in lost revenue from 2025 through 2030. In spite of these upcoming obstacles, is Pfizer still a buy?